Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.

Wolfe GI, Barohn RJ, Foster BM, Jackson CE, Kissel JT, Day JW, Thornton CA, Nations SP, Bryan WW, Amato AA, Freimer ML, Parry GJ; Myasthenia Gravis-IVIG Study Group.

Muscle Nerve. 2002 Oct;26(4):549-52.

PMID:
12362423
2.

IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.

Zinman L, Ng E, Bril V.

Neurology. 2007 Mar 13;68(11):837-41.

PMID:
17353471
3.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka K.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD002277. doi: 10.1002/14651858.CD002277.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD002277.

PMID:
18254004
4.

Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.

Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, Attarian S, Chevret S; Myasthenia Gravis Clinical Study Group.

Arch Neurol. 2005 Nov;62(11):1689-93.

PMID:
16286541
5.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka KV.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD002277. doi: 10.1002/14651858.CD002277.pub4. Review.

PMID:
23235588
6.

IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.

Dhawan PS, Goodman BP, Harper CM, Bosch PE, Hoffman-Snyder CR, Wellik KE, Wingerchuk DM, Demaerschalk BM.

Neurologist. 2015 May;19(5):145-8. doi: 10.1097/NRL.0000000000000026.

PMID:
25970838
7.

Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.

Eienbröker C, Seitz F, Spengler A, Kurz H, Seipelt M, Sommer N, Oertel WH, Timmesfeld N, Tackenberg B.

Muscle Nerve. 2014 Dec;50(6):999-1004. doi: 10.1002/mus.24259. Epub 2014 Oct 30.

PMID:
24710856
8.

IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies.

Zinman L, Bril V.

Ann N Y Acad Sci. 2008;1132:264-70. doi: 10.1196/annals.1405.038.

PMID:
18567877
9.

Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.

Liu JF, Wang WX, Xue J, Zhao CB, You HZ, Lu JH, Gu Y.

Ther Apher Dial. 2010 Apr;14(2):153-60. doi: 10.1111/j.1744-9987.2009.00751.x.

PMID:
20438536
10.

Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.

Gajdos P, Chevret S.

Ann N Y Acad Sci. 2008;1132:271-5. Epub 2007 Dec 20.

PMID:
18096850
11.

A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients.

Alipour-Faz A, Shojaei M, Peyvandi H, Ramzi D, Oroei M, Ghadiri F, Peyvandi M.

Acta Neurol Belg. 2017 Mar;117(1):245-249. doi: 10.1007/s13760-016-0689-z. Epub 2016 Aug 16.

PMID:
27530310
12.

IVIG and PLEX in the treatment of myasthenia gravis.

Bril V, Barnett-Tapia C, Barth D, Katzberg HD.

Ann N Y Acad Sci. 2012 Dec;1275:1-6. doi: 10.1111/j.1749-6632.2012.06767.x.

PMID:
23278570
13.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka K.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002277. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD002277.

PMID:
16625559
14.

Intravenous immunoglobulin for myasthenia gravis.

Gajdos P, Chevret S, Toyka K.

Cochrane Database Syst Rev. 2003;(2):CD002277. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD002277.

PMID:
12804431
15.

Comparison of IVIg and PLEX in patients with myasthenia gravis.

Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V.

Neurology. 2011 Jun 7;76(23):2017-23. doi: 10.1212/WNL.0b013e31821e5505. Epub 2011 May 11.

16.

Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.

Barnett C, Wilson G, Barth D, Katzberg HD, Bril V.

J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):94-7. doi: 10.1136/jnnp-2011-301449. Epub 2012 Nov 15.

PMID:
23154126
17.

Surrogate therapeutic outcome measures in patients with myasthenia gravis.

Zinman L, Baryshnik D, Bril V.

Muscle Nerve. 2008 Feb;37(2):172-6.

PMID:
17918748
18.

High-dose intravenous immunoglobulin G treatment of myasthenia gravis.

Ferrero B, Durelli L.

Neurol Sci. 2002 Apr;23 Suppl 1:S9-24. Review.

PMID:
12032583
19.

Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.

Alabdali M, Barnett C, Katzberg H, Breiner A, Bril V.

Expert Rev Clin Immunol. 2014 Dec;10(12):1659-65. doi: 10.1586/1744666X.2014.971757. Epub 2014 Oct 20. Review.

PMID:
25331319
20.

Immunoglobulin treatment in refractory Myasthenia gravis.

Achiron A, Barak Y, Miron S, Sarova-Pinhas I.

Muscle Nerve. 2000 Apr;23(4):551-5.

PMID:
10716766

Supplemental Content

Support Center